FDA Approves Vaprisol
Vaprisol Astellas Pharma US, Inc. - Treatment for Euvolemic HyponatremiaVaprisol is an arginine vasopressin (AVP) antagonist indicated for the treatment of euvolemic hyponatremia in hospitalized patients.
Posted: December 2005
- FDA Approves Astellas' Vaprisol (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia - October 22, 2008
- FDA Approves Astellas' Vaprisol for the Treatment of Hypervolemic Hyponatremia - March 2, 2007
- FDA Issues Approvable Letter for Yamanouchi's Investigational Hyponatremia Treatment Conivaptan Hydrochloride Injection - December 1, 2004
- Yamanouchi Pharma America Submits New Drug Application to the FDA for Conivaptan Hydrochloride to treat Hyponatremia - February 2, 2004